|
Antiangiogenic drug-induced proteinuria as a predictive factor in metastatic colorectal cancer. |
| |
|
Honoraria - BMSi; Ipsen; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Accord Healthcare; BMSi; Merck; Novartis; Roche |
Research Funding - Astellas Amgen BioPharama; AstraZeneca; Canfite; Merck; Roche; Samsung Bioepis |
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; AstraZeneca; BMSi; Boehringer Ingelheim; Janssen; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; BMSi; MSD; Roche |
Speakers' Bureau - AstraZeneca; BMSi; MSD; Pfizer; Roche; Sandoz |
| |
|
No Relationships to Disclose |